Table 2.
Quality assessment.
| Study | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| AMPLIFY, 2013 | L | L | L | L | L | L | L |
| EINSTEIN-DVT, 2010 | L | U | H | L | L | L | L |
| EINSTEIN-PE, 2012 | L | U | H | L | L | L | L |
| Hokusai-VTE, 2013 | L | U | L | L | L | L | L |
| RE-COVER I, 2009 | L | L | L | L | L | L | L |
| RE-COVER II, 2014 | L | U | L | L | L | L | L |
| Hokusai-Cancer, 2017 | L | U | H | L | L | L | L |
| MAGELLAN, 2013 | L | U | L | L | L | L | L |
| ADOPT, 2011 | L | U | L | L | L | L | L |
L, low risk; U, unclear risk; H, high risk.